Core Viewpoint - Huaren Pharmaceutical (300110) announced the appointment of Mr. Li Jian as a non-independent director of the company's eighth board of directors [1] Group 1 - The company has agreed to the re-election of Mr. Li Jian [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-066 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载，误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决提案的情况； 华仁药业股份有限公司 2025 年第二次临时股东会决议公告 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开及召集情况 1、会议通知情况：华仁药业股份有限公司（以下简称"公司"）2025年9月29 日以董事会公告方式向全体股东发出召开2025年第二次临时股东会的通知。 2、会议召开时间： （1）现场会议召开时间：2025年10月15日14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年10月15日上午9:15-9:25，9:30-11:30和下午13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为：2025年10月15日上午9:15-下午 15:00期间的任意时间。 3、会议召开地点：山东省青岛市高科技工业园株洲路187号公司会议室。 4、会议召集人：公司董事会。 5、会议召开方式：采取现场投票与网络投票相结合的 ...

北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第二次临时股东会的 法律意见书 北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第二次临时股东会的 法律意见书 植德青（会）字[2025]0003 号 致：华仁药业股份有限公司（华仁药业/贵公司） 北京植德（青岛）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2025 年第二次临时股东会（以下简称"本次会议"）。 植德青（会）字[2025]0003 号 二〇二五年十月 山东省青岛市崂山区香岭路 1 号资源博雅广场 4 号楼 10 层 邮编：266000 10th Floor, Building 4, Resources Boya Plaza, No.1 Xiangling Road, Laoshan District, Qingdao City, Shandong Province 266000 P.R.C www.meritsandtree.com 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-067 李健先生，1982 年 10 月出生，中国国籍，中共党员，无境外永久居留权， 医学博士，副主任医师。曾先后供职于总后勤部青藏兵站部、解放军总医院海南 分院、解放军总医院、解放军总医院第一医学中心等单位的多个医疗和管理岗位， 现任华仁药业董事、总裁。 华仁药业股份有限公司 李健先生未持有公司股份，与持有公司 5%以上股份的股东、实际控制人、 公司其他董事、高级管理人员不存在关联关系；不存在《公司法》第一百七十八 条、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》第 3.2.3 条、第 3.2.4 条规定的情形；未受过中国证监会及其他有关部门的处 罚和证券交易所纪律处分，不存在因涉嫌犯罪被司法机关立案侦查或者涉嫌违法 违规被中国证监会立案稽查尚未有明确结论的情形，未曾被中国证监会在证券期 货市场违法失信信息公开查询平台公示或者被人民法院纳入失信被执行人名单； 符合有关法律法规、规范性文件等规定的任职条件。 关于完成补选第八届董事会非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 ...

Core Viewpoint - The announcement from Huaren Pharmaceutical indicates that shareholder Hongta Innovation has reduced its stake in the company by selling 11.82 million shares at an average price of 3.38 yuan, resulting in a reduction of ownership to 4.72% [1] Summary by Relevant Sections - **Shareholder Activity** - Hongta Innovation sold a total of 11.82 million shares through centralized bidding from August 26, 2025, to January 10, 2025 [1] - The average selling price was 3.38 yuan per share, leading to a total reduction in ownership by 1.00% [1] - After the sale, Hongta Innovation holds 55.8231 million shares, which is now below the 5% threshold for significant shareholders [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-065 华仁药业股份有限公司 关于股东减持计划实施完成的公告 股东红塔创新投资股份有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证 公告内容与信息披露义务人提供的信息一致。 华仁药业股份有限公司（以下简称"华仁药业"或"公司"）于2025年8月4日披 露了股东红塔创新投资股份有限公司（以下简称"红塔创新"）《关于持股5%以 上股东减持计划预披露的公告》（公告编号：2025-047），红塔创新计划自减持 计划公告之日起十五个交易日后的三个月内通过集中竞价交易方式减持不超过 公司总股本1%的股份，即不超过11,820,000股。 公司于2025年9月9日披露了《关于持股5%以上股东持股比例变动至5%以下 暨权益变动的提示性公告》（公告编号：2025-060）及《简式权益变动报告书》， 红塔创新持有公司股份比例降至4.999999%，不再是公司持股5%以上股东。 近日，公司收到红塔创新《关于减持华仁药业股份计划实施结果的告知函》， 红塔创新上述减持计划已实施完成。现将具体情况公告如下： ...

Group 1: Stock Performance and Financing - On September 30, Huaren Pharmaceutical's stock increased by 0.62%, with a trading volume of 42.32 million yuan [1] - The financing buy-in amount for Huaren Pharmaceutical on the same day was 4.40 million yuan, while the financing repayment was 5.92 million yuan, resulting in a net financing buy of -1.52 million yuan [1] - As of September 30, the total margin balance for Huaren Pharmaceutical was 249 million yuan, accounting for 6.48% of its market capitalization, indicating a high level compared to the past year [1] Group 2: Business Overview - Huaren Pharmaceutical, established on May 20, 1998, and listed on August 25, 2010, is located in Qingdao, Shandong Province [1] - The company's main business includes large-volume intravenous solutions, peritoneal dialysis solutions, respiratory medications, narcotic medications, raw materials, medical packaging, medical devices, and health products [1] - The revenue composition of Huaren Pharmaceutical is as follows: basic intravenous solutions 40.63%, peritoneal dialysis solutions 34.90%, therapeutic preparations 14.92%, medical devices 8.14%, and others 1.41% [1] Group 3: Shareholder Information and Financial Performance - As of September 20, Huaren Pharmaceutical had 40,500 shareholders, a decrease of 1.46% from the previous period, with an average of 29,156 circulating shares per shareholder, an increase of 1.48% [2] - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2] Group 4: Dividend Information - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3]

Core Viewpoint - Huaren Pharmaceutical (300110) announced the board's approval to elect Mr. Li Jian as a candidate for the non-independent director of the eighth board of directors [1] Summary by Category - **Company Announcement** - The board of Huaren Pharmaceutical has agreed to elect Mr. Li Jian as a candidate for the non-independent director position [1]

Core Viewpoint - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement project in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Participation - Huarun Pharmaceutical and its wholly-owned subsidiaries, Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huarun Pharmaceutical (Rizhao) Co., Ltd., actively engaged in the bidding process for the procurement project [1] - The project is identified as "LH-YD2025-1" and involves both Western medicine and traditional Chinese medicine [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has announced the selection results, confirming that Huarun Pharmaceutical's products, including mixed sugar electrolyte injection, betahistine hydrochloride sodium injection, and hydroxyethyl starch 130/0.4 sodium chloride injection, have been chosen for this procurement [1]

Group 1 - Huarun Pharmaceutical held a temporary board meeting on September 29, 2025, to discuss the election of a non-independent director [1] - For the first half of 2025, Huarun Pharmaceutical's revenue composition was 95.79% from pharmaceutical manufacturing and 4.21% from pharmaceutical commerce [1] - As of the report date, Huarun Pharmaceutical's market capitalization was 3.8 billion yuan [1] Group 2 - The competition between Nongfu Spring and Yibao has intensified, with Nongfu Spring's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [1]